Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 92% Improvement Relative Risk ICU admission -22% Days alive and discharged.. -8% HCQ  ProPAC-COVID  LATE TREATMENT  DB RCT Is late treatment with HCQ beneficial for COVID-19? Double-blind RCT 117 patients in Denmark (April - December 2020) Lower mortality with HCQ (not stat. sig., p=0.32) c19hcq.org Sivapalan et al., European Respiratory.., Jun 2021 Favors HCQ Favors control

Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial

Sivapalan et al., European Respiratory Journal, doi:10.1183/13993003.00752-2021, ProPAC-COVID, NCT04322396
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Early terminated late stage (8 days from onset, 59% on oxygen) RCT not showing statistically significant differences. NNF20SA0062834.
risk of death, 92.0% lower, RR 0.08, p = 0.32, treatment 1 of 61 (1.6%), control 2 of 56 (3.6%), adjusted per study.
risk of ICU admission, 22.4% higher, RR 1.22, p = 1.00, treatment 4 of 61 (6.6%), control 3 of 56 (5.4%).
relative days alive and discharged from hospital within 14 days (inverse), 8.4% worse, RR 1.08, p = 0.36, treatment 61, control 56, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sivapalan et al., 3 Jun 2021, Double Blind Randomized Controlled Trial, Denmark, peer-reviewed, 32 authors, study period 6 April, 2020 - 21 December, 2020, average treatment delay 8.0 days, trial NCT04322396 (history) (ProPAC-COVID).
This PaperHCQAll
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial
MD, PhD Pradeesh Sivapalan, Charlotte Suppli Ulrik, MD Therese Sophie Lapperre, Dahlin Rasmus, Josefin Bojesen, Andrea Eklöf, Jon Torgny Browatzki, Vibeke Wilcke, Kjell Gottlieb, Julius Erik, Casper Håkansson, Oliver Tidemandsen, Howraman Tupper, Christina Marisa Meteran, Eva Bergsøe, Uffe Brøndum, Daniel Bech Bodtger, Sidse Graff Rasmussen, Lars Jensen, Alexander Pedersen, Helene Jordan, Christian Priemé, Ida Elisabeth Søborg, Dorthe Steffensen, Tobias Wirenfeldt Høgsberg, Martin Klausen, Peter Steen, Asger Lange, Muhzda Sverrild, Filip Krag Ghanizada, Tor Knop, Jens D Biering-Sørensen, Jens-Ulrik Staehr Lundgren, Jensen, MD, DMSc Charlotte Suppli Ulrik, PhD ; Rasmus, MD Dahlin Bojesen, PhD Josefin Eklöf, MD, PhD Andrea Browatzki, MD Jon Torgny Wilcke, PhD Vibeke Gottlieb, PhD Kjell Erik, MD Julius Håkansson, MD Casper Tidemandsen, MD Oliver Tupper, PhD Howraman Meteran, MD Christina Bergsøe, BSc Eva Brøndum, RN Uffe Bodtger, PhD ; Daniel, MD Bech Rasmussen, PhD ; Sidse, MD, PhD Graff Jensen, MD Lars Pedersen, PhD Alexander Jordan, BSc Helene Priemé, PhD Christian Søborg, MD, PhD Ida E Steffensen, PhD Dorthe Høgsberg, RN ; Tobias, MSc Wirenfeldt Klausen, PhD Martin Steen Frydland, PhD Peter Lange, MD, DMSc Asger Sverrild, MD, PhD; Muhzda Ghanizada, MD Filip Krag Knop, PhD Tor Biering-Sørensen, PhD, MPH Jens D Lundgren, MD, DMSc Jens-Ulrik Staehr Jensen, Senior Consultant, Research Associate Professor, MD, PhD. Jens-Ulrik Staehr Jensen, Suppli Ulrik, Andrea Bojesen, Howraman Djurhuus Tupper, Uffe Bergsøe, Steinholtz Christian, Daniel Bech Bødtger, Helene Pedersen, Steffensen, Sandbaek Dorthe, Martin Høgsberg, Peter Steen Frydland, Muzhda Sverrild, Jens-Ulrik Ghanizada, Staehr Jensen, Tobias Wirenfeldt Klausen, Jens D Lundgren, MD Andrea Browatzki Senior Consultant, Christian Laursen, Ulla Weinreich
doi:10.1183/13993003.00752-2021)
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19 -a randomised doubleblinded placebo-controlled trial by the ProPAC-COVID study group* *A complete list of members in the Proactive Protection with Azithromycin and hydroxy-Chloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID) Study Group is provided in Supplementary Appendix 3. The ProPAC-COVID study is an initiative by the independent research network COP:TRIN (www.coptrin.dk). The members of the writing group
For the secondary ordinary outcome, we will use a Wilcoxon rank sum test. The primary outcome uses an ordinal severity scale with 8 categories, analyzed using the proportional odds model. The key parameter of interest is the "common odds ratio," which quantifies the shift in the severity distribution resulting from treatment. For an efficacious treatment, an odds ratio greater than 1 quantifies an improvement in disease severity; a value of 2 indicates a bigger improvement than a value of 1.25. Sample size The power to avoid type II error is 80% (1-β) at a two-sided 5% significance level, using a t-test for the primary outcome, and a group-sequential design allowing for one interim analysis at half target recruitment. This provides a sample size of 226 subjects. All confidence intervals reported will be 95% confidence intervals. Analysis Software All analyses will be performed using SAS software version 9.4. DATA ANALYSIS Descriptive analyses -Baseline characteristics at study enrollment (defined as day 1). The following baseline characteristics of the study population will be summarized separately within each randomized group: Primary objective and outcome The primary outcome is "days alive and out of hospital (DAOH) within 14 days after recruitment" defined as the time from hospital discharge and days without hospitalization up to 14 days from recruitment where the patient is alive. Data for the primary outcome analysis will be presented as mean..
References
Albert, Connett, Bailey, Casaburi, Cooper et al., Azithromycin for prevention of exacerbations of COPD, N Engl J Med
Altenburg, De Graaff, Stienstra, Sloos, Van Haren et al., Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial, JAMA
Altenburg, De Graaff, Stienstra, Sloos, Van Haren et al., Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial, JAMA
Ariti, Cleland, Pocock, Pfeffer, Swedberg et al., Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program, Am Heart J
Bach, Conducted and reported
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19 -Final Report, N Engl J Med
Beigelman, Mikols, Gunsten, Cannon, Brody et al., Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis, Respir Res
Borba, Val, Sampaio, Alexandre, Melo et al., Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial, JAMA Netw Open
Cantini, Goletti, Petrone, Fard, Niccoli et al., Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review, Drugs
Casadevall, Dragotakes, Johnson, Senefeld, Klassen et al., Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Convalescent Plasma Hesitancy cost lives? medRxiv
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Coalition Covid-19 Brazil II. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N Engl J Med
Chalmers, Boersma, Lonergan, Jayaram, Crichton et al., Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis, Lancet Respir Med
Chalmers, Crichton, Goeminne, Cao, Humbert et al., Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
Colson, Rolain, Raoult, Chloroquine for the 2019 novel coronavirus SARS-CoV-2, Int J Antimicrob Agents
Dizziness, Corneal Oedema, Double Vision, Retinopathy, Cramps, Neuropathy, Palsy, Psychosis, Suicidal behaviour. Acute generalized exanthematous pustulosis***, Exfoliative dermatitis, Erythema multiforme, Photosensitivity, Stevens-Johnson syndrome, Toxic epidermal necrolysis. Allergic reactions (including DRESS syndrome), Angioedema. Hearing loss, Macular and retinal degeneration, Maculopathy
Fantini, Chahinian, Yahi, Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal, Int J Antimicrob Agents
Fantini, Scala, Chahinian, Yahi, Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection, Int J Antimicrob Agents
Finfer, Bellomo, Why publish statistical analysis plans?, Crit Care Resusc
Freund, Cachanado, Delannoy, Laribi, Yordanov et al., Effect of an Emergency Department Care Bundle on 30-Day Hospital Discharge and Survival Among Elderly Patients With Acute Heart Failure: The ELISABETH Randomized Clinical Trial, JAMA
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gibson, Yang, Upham, Reynolds, Hodge et al., Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial, Lancet
Gielen, Johnston, Edwards, Azithromycin induces anti-viral responses in bronchial epithelial cells, Eur Respir J
Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Group, Horby, Mafham, Linsell, Bell et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Group, Lundgren, Grund, Barkauskas, Holland et al., A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19, N Engl J Med
Hiles, Mcdonald, Guilhermino, Brusselle, Gibson, Does maintenance azithromycin reduce asthma exacerbations? An individual participant data metaanalysis, Eur Respir J
Horby, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet
Kawamura, Ichikado, Takaki, Eguchi, Anan et al., Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center, Int J Antimicrob Agents
Kawamura, Ichikado, Takaki, Eguchi, Anan et al., Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center, Int J Antimicrob Agents
Lee, Silverman, Bargman, The role of antimalarial agents in the treatment of SLE and lupus nephritis, Nat Rev Nephrol
Lee, Silverman, Bargman, The role of antimalarial agents in the treatment of SLE and lupus nephritis, Nat Rev Nephrol
Li, Zu, Deng, Li, Parvatiyar et al., Azithromycin Protects against Zika virus Infection by Upregulating virus-induced Type I and III Interferon Responses, Antimicrob Agents Chemother
Medical, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, JAMA
Mehra, Desai, Ruschitzka, Patel, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet
Mercuro, Yen, Shim, Maher, Mccoy et al., Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19), JAMA Cardiol
Nugroho, Suryantoro, Yuliasih, Rosyid, Asmarawati et al., Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis
O'brien, Fleming, A multiple testing procedure for clinical trials, Biometrics
Pradeesh Sivapalan, Ph, Suppli Ulrik, Sc, Sophie Lapperre et al., Supplemental Appendix 3 -Online Content Proactive protection with azithromycin and hydroxychloroquine in hospitalised patients with COVID-19 (ProPAC-COVID): A randomised clinical trial Authors: The members of the writing group
Roden, Harrington, Poppas, Russo, Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment, Circulation
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis
Segal, Clemente, Wu, Wikoff, Gao et al., Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung, Thorax
Self, Semler, Leither, Casey, Angus et al., Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial, JAMA
Sivapalan, Lapperre, Janner, Laub, Moberg et al., Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial, Lancet Respir Med
Sivapalan, Lapperre, Janner, Laub, Moberg et al., Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial, Lancet Respir Med
Sivapalan, Ulrik, Bojesen, Lapperre, Eklof et al., Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial, Trials
Sivapalan, Ulrik, Lappere, Eklof, Shaker et al., Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan, Trials
Svorre, Bach, Med, Respiratory Research Unit, Section of
Uncommon ; Pain, Hepatitis, Oral candidiasis. Dyspnea, Pneumonia, Oedema. Eosinophilia, Leukopenia, Neutropenia. Elevated serum bicarbonate, Hyperchloremia, Hyperglycaemia, Hyperkalaemia, Hypernatremia, Hypokalaemia, Hyponatraemia. Arthritis, Back Pain. Nervousness, Somnolence. Facial oedema, Dermatitis, Photosensitivity. Candidiasis, Infections. Metrorrhagia, Kidney Pain, Testicular
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J
Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J
Walters, Tan, White, Gibson, Wood-Baker et al., Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease, Cochrane Database Syst Rev
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit